Soligenix Receives UK Promising Innovative Medicine Designation for SGX945 in Behcet Disease Treatment

Soligenix announced that SGX945 (dusquetide) has received Promising Innovative Medicine designation from the U.K. Medicines and Healthcare Products Regulatory Agency for the treatment of Behcet's Disease. This designation represents the first step toward potential inclusion in the U.K.'s Early Access to Medicines Scheme, which allows patients with life-threatening or seriously debilitating conditions to access promising therapies earlier. The PIM designation was granted based on Phase 2 clinical data indicating that dusquetide may provide a significant advantage over existing treatments while demonstrating a favorable potential benefit-risk profile for patients with this rare inflammatory disorder.

The importance of this development lies in addressing a significant unmet medical need for Behcet's Disease patients who currently have limited treatment options. Behcet's Disease is a rare inflammatory disorder that can affect multiple body systems, including blood vessels, skin, joints, and the digestive tract. The condition can lead to serious complications and significantly impact patients' quality of life. The PIM designation acknowledges that SGX945 has shown promising early clinical data suggesting it could offer meaningful benefits over currently available therapies.

This regulatory milestone is particularly significant because it accelerates the pathway for patients to access potentially beneficial treatments before full marketing authorization is granted. The Early Access to Medicines Scheme provides a framework for patients with serious conditions to receive medicines that have demonstrated promising efficacy and safety in clinical trials but have not yet completed the full regulatory approval process. This can be especially important for rare diseases like Behcet's Disease, where treatment options are limited and patients often face significant challenges in managing their condition.

The clinical data supporting this designation comes from Phase 2 studies that evaluated dusquetide's effectiveness in treating inflammatory diseases. As an innate defense regulator technology, dusquetide represents a novel approach to modulating the body's immune response to inflammation. This mechanism of action differs from existing treatments, potentially offering advantages in terms of efficacy, safety, or both. The company's development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.

This designation represents a validation of the scientific approach behind SGX945 and provides momentum for further clinical development. It also highlights the growing recognition of the need for innovative treatments for rare inflammatory disorders. The company's broader portfolio includes development programs for HyBryte for cutaneous T-cell lymphoma and vaccine candidates targeting various infectious diseases. The development of vaccine programs incorporates proprietary heat stabilization platform technology known as ThermoVax, which has been supported with government grant and contract funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. For more information about the company's regulatory filings and risk factors, investors can refer to the company's most recent Annual Report on Form 10-K available through the SEC's EDGAR system at https://www.sec.gov/edgar.shtml.